Business Context and Reporting Period
Company: Assembly Biosciences, Inc. (ASMB)
Filing Type: Form 8-K (Current Report)
Report Date: August 13, 2026
Reporting Period: Quarter ended June 30, 2026
Context: The filing announces the issuance of a press release detailing financial results for the second quarter of 2026.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific figures within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Material Changes
The filing text does not provide specific numerical comparisons or descriptions of material changes versus the prior comparable period. It only confirms that results for the quarter ended June 30, 2026, were announced.
Guidance, Outlook, and Risks
Management Commentary: The filing states that a press release was issued on August 13, 2026, but the content of that commentary is not included in the provided text.
Guidance and Outlook: Not provided in this text.
Risks and Contingencies: Not provided in this text.
Unusual Items: Not provided in this text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 13, 2026) for actual revenue, net loss, and cash position figures.
- Verify year-over-year and quarter-over-quarter growth rates in the full press release.
- Check for updated operational milestones or product pipeline developments mentioned in the attached press release.
- Confirm cash runway and burn rate details which are absent from this summary filing.